The TARGET-IV Trial: International Multicenter Randomized Assessment of the Firehawk® Rapamycin Eluting Coronary Stent System
Presenter:
We Recommend
Disclosures
Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:
- Equity/Stock(s)/Options - Nanostent
- Consultant Fee/Honoraria/Speaker's Bureau - Microport; Opsens; Boston Scientific Corporation